Simtriyo (Centanafadine): The New ADHD Medication Changing the Game

Key Facts at a Glance

Why This Approval Matters

ADHD is one of the most common neurodevelopmental conditions in the world, affecting an estimated 22.5 million children, adolescents, and adults in the United States. Until this approval, the entire medication toolkit rested on two mechanisms: dopamine and norepinephrine reuptake inhibition (the stimulants) or largely selective norepinephrine reuptake inhibition (the non-stimulants).

Simtriyo adds a third neurotransmitter to the picture. Whether that translates into better real-world outcomes for any individual person is still an open question — but mechanistically, it is the first meaningfully new option in years.

How Simtriyo Works Compared to Existing ADHD Medications

Simtriyo is described as a norepinephrine, dopamine, and serotonin reuptake inhibitor — an NDSRI, or triple reuptake inhibitor. Here is how that lines up against the medications most people are already familiar with:

If you are still deciding between the established stimulant options, our breakdown of Adderall vs. Vyvanse vs. Concerta covers duration, onset, and side-effect differences in detail.

What the Trials Showed

Approval was supported by Phase 3 randomized, double-blind, placebo-controlled trials in both adults and pediatric patients, using standard rating scales such as the ADHD-RS-5 and AISRS. Both age groups showed statistically significant and clinically meaningful improvement in core symptoms versus placebo.

The detail clinicians keep returning to is speed: improvements were observed as early as Week 1. For families who have spent six weeks waiting to find out whether a non-stimulant is going to work, that early signal matters.

Dosing and How It Is Taken

• •Adults: 210 mg once daily to start, increased to a maximum of 280 mg once daily if needed.
• •Children and adolescents 6 and older: dosed per the label, requiring a minimum weight of 20 kg (~44 lbs).
• •Swallow the extended-release capsule whole — do not crush, chew, or break it.
• •It may be taken with or without food.

Side Effects and What Should Be Monitored

Reported adverse events in this class commonly include decreased appetite, nausea, dry mouth, headache, difficulty sleeping, and increases in heart rate and blood pressure. Children and adolescents may report appetite and sleep changes most prominently. Full details belong in the prescribing information and in a conversation with your clinician.

• •Blood pressure and heart rate at baseline and on follow-up
• •Weight, appetite, and (in children) growth trajectory
• •Sleep quality and onset — timing of the dose can matter
• •Mood, irritability, and anxiety symptoms, especially early on
• •A complete medication and supplement list to screen for interactions
• •Clear counseling about the alcohol warning before the first dose

Interactions are worth a careful review before any switch — our guide to medications that can affect ADHD medication walks through the common ones.

Who Might Be a Good Candidate?

If emotional intensity and criticism sensitivity are the parts of ADHD that hit hardest for you, read rejection sensitive dysphoria and ADHD and executive dysfunction.

When Will Simtriyo Be Available?

As of August 2026, Simtriyo was FDA-approved but not yet commercially available. Before launch, it must be scheduled under the Controlled Substances Act by the DEA. Availability is expected later in 2026.

In the meantime, the practical step is not to wait passively. If your current regimen is not working well, that is worth addressing now — and if Simtriyo looks like a candidate later, you and your prescriber will already have a documented history of what has and has not worked.

A Note on Nevada and Controlled Substances

Our practice does not prescribe controlled substances for patients in Nevada. If Simtriyo receives a DEA control schedule, that limitation would apply to it as well for Nevada patients, while non-controlled ADHD options such as atomoxetine and viloxazine remain available through telehealth psychiatry in Nevada. Patients in Florida and Wisconsin have the full range available. See also how online ADHD treatment works.

How to Bring It Up With Your Prescriber

Frequently Asked Questions

A New Option — Not a Cure-All, But a Real Advance

A new mechanism is genuinely good news, especially for people who have cycled through options without finding a good fit. It is not a reason to abandon something that is working. The best ADHD care still comes from careful diagnosis, honest tracking of what changes, and a prescriber who adjusts based on your response rather than the newest name.